Dualsystems Biotech AG Press Release
Dualsystems Biotech AG collaborates with Shantani Proteome Analytics Pvt. Ltd. to partner business development activities for the two companies
Schlieren, Switzerland, Feb. 2016: – Dualsystems Biotech AG has announced today it will partner with Shantani Proteome Analytics Pvt. Ltd. to support each other in business development.
The partnership will combine the complementary strengths of Dualsystems, a leading service provider for target deconvolution of large molecules with the strengths of Shantani a leading service providing company for target deconvolution of small molecules.
Dualsystems provides the ligand-receptor capture (LRC-TriCEPS) technology developed by Prof. Bernd Wollscheid and licensed in from the ETHZ. The LC-MS/MS based technique is the only technology worldwide to identify the unknown receptors of a ligand on the living cells. The LRC-TriCEPS Technology uses a proprietary tri functional crosslinker molecule called TriCEPSTM to identify targets for large molecules (biotherapeutics/biologics) located in the cell membrane. The technology is able to identify the targets of peptides, proteins, antibodies and viruses while the target cell is still alive during ligand-target interaction. Next to the main targets, the technology will also identify off targets and therefore provides crucial information for selecting the right drug candidate.
Shantani is a privately-held biotechnology company that provides customized target identification solutions utilizing both traditional and novel chemical-proteomics based technologies. Shantani’s proprietary technology portfolio include Unique Polymer Technology (UPT) that utilizes specifically designed affinity matrix to immobilize the small molecule without any need of its derivatization and Sub Cellular Location Specific Target Capture Technology (SCLS) that utilizes sub-cellular location specific peptide probes to capture targets from specific cellular location. These technologies can achieve false positive target identification rates as low as 20%. Shantani’s technologies provides an unbiased approach to identify few yet ‘rightful’ targets of small molecule that eventually adds in lead optimization, lead selectivity/toxicity profiling and understanding action mechanism of the small molecule.